Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Zoledronate may prevent bone loss and stop the growth of cancer cells in bone.
Thalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It is
not yet know whether giving zoledronate together with thalidomide is more effective than
zoledronate alone in treating multiple myeloma.
PURPOSE: This randomized phase III trial is studying zoledronate and thalidomide see how well
they work compared with zoledronate alone in treating patients with early stage multiple
myeloma.